

# Minimal Residual Disease Testing: Global Markets and Technologies

<https://marketpublishers.com/r/M9926F265F52EN.html>

Date: July 2023

Pages: 152

Price: US\$ 5,500.00 (Single User License)

ID: M9926F265F52EN

## Abstracts

### Report Scope:

The report's scope includes an overview of the global market on minimal residual disease testing and an analysis of global market trends, using 2022 as the base year and forecasting 2023 through 2028 with a compound annual growth rate (CAGR) projection.

The report analyzes leading and emerging technologies, applications, end-user, and product pipeline details for minimal residual disease testing. Profiles of leading market players, their specific products, financial information, and recent market activities are provided. This report also assesses companies' mergers and acquisitions and funding activities and their impact in the face of the competitive environment. The report details the minimal residual disease testing market based on technology, application, and end user. The market is segmented into polymerase chain reaction (PCR), next-generation sequencing (NGS), flow cytometry, and others based on technology.

The market is categorized as hematological malignancies [leukemia, lymphoma (non-Hodgkin lymphoma, Hodgkin lymphoma), myeloma], solid tumors, and others based on application. The report also considers the impact of the Covid-19 pandemic on this market. Regional analysis includes North America (U.S., Canada, and Mexico), Europe (U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of Asia-Pacific), and the Rest of the World (South America and the Middle East and Africa).

### Report Includes:

44 data tables and 45 additional tables

An up-to-date overview and in-depth analysis of the global markets for minimal residual disease (MRD) testing

Analyses of the global market trends, historical market revenue (sales figures) data from 2021-2022, estimates for 2023 and projections of compound annual growth rates (CAGRs) through 2028

Estimation of the actual market size and revenue forecast for global minimal residual disease testing market in USD million values, and corresponding market share analysis based on technology, application, and region

In-depth information (facts and figures) concerning the market growth drivers, opportunities and challenges, prospects, technologies, regulatory scenarios, and the impact of COVID-19 on the progress of this market

Detailed description of specific somatic or germline mutations that serve as precise markers to diagnose cancer during ongoing investigations

Coverage of major cancers such as leukemia, lymphoma, and multiple myeloma, and discussion on how MRD level monitoring enables more precise evaluations, thereby identifying the amount of risk or enabling early prevention of future relapse

Discussion of the importance of ESG in global minimal residual disease testing market, consumer attitudes, risks and opportunity assessment, future trends, and ESG followed practices within the industry

A look at the major vendors in minimal residual disease testing market, and analyze the structure of this industry with respect to company market shares, venture fundings, and recent merger and acquisition (M&A) activities

Identification of the major stakeholders and analysis of their company competitive landscape based on recent developments, key financials and segmental revenues, and operational integration

Detailed company profiles of the leading market players, including Adaptive Biotechnologies, Invitae Corp., Guardant Health, Natera Inc., NeoGenomics

Inc., Exact Sciences Corp., and Quest Diagnostics

## Contents

### **CHAPTER 1 INTRODUCTION**

Study Goals and Objectives  
Reasons for Doing This Study  
Scope of Report  
Research Methodology  
Information Sources  
Geographic Breakdown

### **CHAPTER 2 SUMMARY AND HIGHLIGHTS**

Market Outlook

### **CHAPTER 3 MARKET OVERVIEW**

Definition of Minimal Residual Disease  
Importance of Detecting Minimal Residual Disease  
Indications for Minimal Residual Disease Testing  
Techniques Used for Detecting Minimal Residual Disease

### **CHAPTER 4 MARKET DYNAMICS**

Market Dynamics  
Drivers  
Restrains  
Opportunities  
Impact of Covid-19 on Minimal Residual Disease Testing Market  
Regulatory Landscape  
Clinical Laboratory Improvement Amendments of 1988 (CLIA)  
State Licensing Laws  
The U.S. Food and Drug Administration

### **CHAPTER 5 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET BY TECHNOLOGY**

Overview  
Flow Cytometry

Polymerase Chain Reaction (PCR)  
Next-Generation Sequencing (NGS)  
Others

## **CHAPTER 6 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET BY APPLICATION**

Overview  
Hematological Malignancies  
Leukemia  
Lymphoma  
Myeloma  
Solid Tumors  
Others

## **CHAPTER 7 GLOBAL MINIMAL RESIDUAL DISEASE TESTING MARKET BY REGION**

North America  
Europe  
Asia-Pacific  
Rest of the World

## **CHAPTER 8 ESG DEVELOPMENTS**

Importance of ESG in Minimal Residual Disease Testing Industry  
ESG Ratings and Metrics: Understanding the Data  
ESG Practices in the Minimal Residual Disease Testing Industry  
Environmental Performance  
Social Performance  
Governance Performance  
Future Trends  
BCC Research Viewpoint

## **CHAPTER 9 EMERGING TECHNOLOGIES AND DEVELOPMENTS**

Emerging Technologies  
Digital Polymerase Chain Reaction (dPCR)

## **CHAPTER 10 M&A ANALYSIS**

M&A Analysis

## **CHAPTER 11 COMPETITIVE INTELLIGENCE**

Top Market Players Ranking, 2022

Key Strategies Adopted by Companies

Collaborations

Marketing Activity

New Product Launch

Expansion

Acquisition

Partnerships, Agreements and Alliances

Clinical Data Studies

Others

## **CHAPTER 12 COMPANY PROFILES**

ADAPTIVE BIOTECHNOLOGIES CORP.

AMGEN INC.

ASTRAZENECA PLC

BIO-RAD LABORATORIES INC.

CERGENTIS B.V.

EXACT SCIENCES CORP.

GUARDANT HEALTH INC.

ILLUMINA INC. (GRAIL LLC)

INVITAE

INVIVOSCRIBE INC.

NATERA INC.

NEOGENOMICS INC.

QIAGEN

SYSMEX CORP.

## List Of Tables

### LIST OF TABLES

Summary Table: Global Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 1: Techniques to Quantify MRD in Multiple Myeloma

Table 2: Advantages and Disadvantages of Available Techniques to Monitor MRD

Table 3: Various Liquid Biopsies for Minimal Residual Disease Testing

Table 4: Total Number of New Cancer Cases and Deaths Due to Various Cancers Globally, 2020

Table 5: Global Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 6: Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, Through 2028

Table 7: Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, Through 2028

Table 8: Global Market for Next-Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, Through 2028

Table 9: Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, Through 2028

Table 10: Global Market for Minimal Residual Disease Testing, by Application, Through 2028

Table 11: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, Through 2028

Table 12: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028

Table 13: Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, Through 2028

Table 14: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, Through 2028

Table 15: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, Through 2028

Table 16: Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, Through 2028

Table 17: Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, Through 2028

Table 18: Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, Through 2028

Table 19: Global Market for Minimal Residual Disease Testing for Solid Tumors, by Region, Through 2028

Table 20: Global Market for Minimal Residual Disease Testing for Other Applications, by Region, Through 2028

Table 21: Global Market for Minimal Residual Disease Testing, by Region, Through 2028

Table 22: North American Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 23: North American Market for Minimal Residual Disease Testing, by Application, Through 2028

Table 24: North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028

Table 25: Estimated Cancer Incidence and Mortality, Age Standardized Rate, by Cancer Type, EU Countries, 2020

Table 26: European Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 27: European Market for Minimal Residual Disease Testing, by Application, Through 2028

Table 28: European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028

Table 29: Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 30: Asia-Pacific Market for Minimal Residual Disease Testing, by Application, Through 2028

Table 31: Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028

Table 32: Rest of the World Market for Minimal Residual Disease Testing, by Technology, Through 2028

Table 33: Rest of the World Market for Minimal Residual Disease Testing, by Application, Through 2028

Table 34: Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, Through 2028

Table 35: ESG Ratings and Metrics

Table 36: Environmental Performance in the Minimal Residual Disease Testing Industry

Table 37: Social Performance in the Minimal Residual Disease Testing Industry

Table 38: Governance Performance in the Minimal Residual Disease Testing Industry

Table 39: Acquisitions in the Minimal Residual Disease Testing Industry, Oct. 2020–Apr. 2023

Table 40: Collaborations: Minimal Residual Disease Testing Market, 2020-2023



Table 41: Marketing Activity: Minimal Residual Disease Testing Market, 2020-2023

Table 42: New Product Launch: Minimal Residual Disease Testing Market, 2020-2023

Table 43: Expansion: Minimal Residual Disease Testing Market, 2020-2023

Table 44: Acquisitions: Minimal Residual Disease Testing Market, 2020-2023

Table 45: Partnerships, Agreements and Alliances: Minimal Residual Disease Testing Market, 2020-2023

Table 46: Clinical Data Studies: Minimal Residual Disease Testing Market, 2020-2023

Table 47: Other Competitive Strategies: Minimal Residual Disease Testing Market, 2020-2023

Table 48: Adaptive Biotechnologies Corp.: Annual Revenue, 2022

Table 49: Adaptive Biotechnologies Corp.: Recent Developments, Nov. 2020–Apr. 2023

Table 50: Adaptive Biotechnologies Corp.: Pipeline Products

Table 51: Adaptive Biotechnologies Corp.: Product Portfolio

Table 52: Amgen Inc.: Annual Revenue, 2022

Table 53: Amgen Inc.: Recent Developments, 2019-2023

Table 54: Amgen Inc.: Product Portfolio

Table 55: AstraZeneca Plc: Annual Revenue, 2022

Table 56: AstraZeneca Plc: Recent Developments, 2020-2023

Table 57: AstraZeneca Plc: Product Portfolio

Table 58: Bio-Rad Laboratories Inc.: Annual Revenue, 2022

Table 59: Bio-Rad Laboratories Inc.: Recent Developments, 2022 and 2023

Table 60: Bio-Rad Laboratories Inc.: Product Portfolio

Table 61: Cergentis B.V.: Recent Developments, 2020-2022

Table 62: Cergentis B.V.: Product Portfolio

Table 63: Exact Sciences Corp.: Annual Revenue, 2021

Table 64: Exact Sciences Corp.: Recent Developments, 2021-2023

Table 65: Exact Sciences Corp.: Product Portfolio

Table 66: Guardant Health Inc.: Annual Revenue, 2022

Table 67: Guardant Health Inc.: Recent Developments, 2021-2023

Table 68: Guardant Health Inc.: Product Portfolio

Table 69: Illumina Inc.: Annual Revenue, 2022

Table 70: Illumina, Inc.: Recent Developments, 2021-2023

Table 71: Illumina Inc.: Product Portfolio

Table 72: Invitae: Annual Revenue, 2022

Table 73: Invitae: Recent Developments, 2020-2023

Table 74: Invitae: Product Portfolio

Table 75: Invivoscribe Inc.: Recent Developments, 2021-2023

Table 76: Invivoscribe Inc.: Product Portfolio

Table 77: Natera Inc.: Annual Revenue, 2022

Table 78: Natera Inc.: Recent Developments, 2022 and 2023

Table 79: Natera Inc.: Product Portfolio

Table 80: NeoGenomics Inc.: Annual Revenue, 2022

Table 81: NeoGenomics Inc.: Recent Developments, 2021-2023

Table 82: NeoGenomics Inc.: Product Portfolio

Table 83: Qiagen N.V.: Annual Revenue, 2022

Table 84: Qiagen N.V.: Recent Developments, 2021-2023

Table 85: Qiagen N.V.: Product Portfolio

Table 86: Sysmex Corp.: Annual Revenue, 2023

Table 87: Sysmex Corp.: Recent Developments, 2021-2023

Table 88: Sysmex Corp.: Product Portfolio

## List Of Figures

### LIST OF FIGURES

Summary Figure: Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 1: Global Estimated New Cancer Cases, by Region, 2020 vs. 2040

Figure 2: Rate of New Malignant Hematologic Cancers, by Age at Diagnosis, 2021

Figure 3: Global Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 4: Global Market for Flow Cytometry for Minimal Residual Disease Testing, by Region, 2021-2028

Figure 5: Global Market for Polymerase Chain Reaction for Minimal Residual Disease Testing, by Region, 2021-2028

Figure 6: Global Market for Next Generation Sequencing (NGS) for Minimal Residual Disease Testing, by Region, 2021-2028

Figure 7: Global Market for Other Technologies for Minimal Residual Disease Testing, by Region, 2021-2028

Figure 8: Global Market for Minimal Residual Disease Testing, by Application, 2021-2028

Figure 9: Distribution Share of Estimated New Cases of Hematological Malignancies, 2021

Figure 10: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Region, 2021-2028

Figure 11: Global Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type, 2021-2028

Figure 12: Global Market for Hematological Minimal Residual Disease Testing for Leukemia, by Region, 2021-2028

Figure 13: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Type, 2021-2028

Figure 14: Global Market for Hematological Minimal Residual Disease Testing for Lymphoma, by Region, 2021-2028

Figure 15: Global Market for Minimal Residual Disease Testing for Non-Hodgkin Lymphoma, by Region, 2021-2028

Figure 16: Global Market for Minimal Residual Disease Testing for Hodgkin Lymphoma, by Region, 2021-2028

Figure 17: Global Market for Hematological Minimal Residual Disease Testing for Myeloma, by Region, 2021-2028

Figure 18: Global Market for Minimal Residual Disease Testing for Solid Tumors, by

Region, 2021-2028

Figure 19: Global Market for Minimal Residual Disease Testing for Other Applications, by Region, 2021-2028

Figure 20: Global Market for Minimal Residual Disease Testing, by Region, 2021-2028

Figure 21: U.S. Elderly (65 and Above) Population, 2010-2050

Figure 22: 5-Year Relative Survival for Malignant Hematologic Cancers, by Cancer Type, 2022

Figure 23: North American Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 24: North American Market for Minimal Residual Disease Testing, by Application, 2021-2028

Figure 25: North American Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028

Figure 26: European Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 27: European Market for Minimal Residual Disease Testing, by Application, 2021-2028

Figure 28: European Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028

Figure 29: Asia-Pacific Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 30: Asia-Pacific Market for Minimal Residual Disease Testing, by Application, 2021-2028

Figure 31: Asia-Pacific Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028

Figure 32: Rest of the World Market for Minimal Residual Disease Testing, by Technology, 2021-2028

Figure 33: Rest of the World Market for Minimal Residual Disease Testing, by Application, 2021-2028

Figure 34: Rest of the World Market for Minimal Residual Disease Testing for Hematological Malignancies, by Type 2021-2028

Figure 35: Snapshot: Key ESG Trends in Minimal Residual Disease Testing Industry

Figure 36: M&A in Minimal Residual Disease Testing Industry, by Year, 2020-2023

Figure 37: Leading Market Players Ranking, 2022

Figure 38: Global Minimal Residual Disease Testing Market Share, Competitive Intelligence, 2020-2023

Figure 39: Adaptive Biotechnologies Corp.: Annual Revenue, 2021 and 2022

Figure 40: Adaptive Biotechnologies Corp.: Revenue Share, by Business Unit, 2021

Figure 41: Amgen Inc.: Annual Revenue, 2021 and 2022

- Figure 42: Amgen Inc.: Revenue Share, by Product, 2022
- Figure 43: Amgen Inc.: Revenue Share, by Geography, 2022
- Figure 44: AstraZeneca Plc.: Annual Revenue, 2021 and 2022
- Figure 45: AstraZeneca Plc: Revenue Share, by Therapy Area, 2022
- Figure 46: AstraZeneca Plc: Revenue Share, by Region, 2022
- Figure 47: Bio-Rad Laboratories Inc.: Annual Revenue, 2021 and 2022
- Figure 48: Bio-Rad Laboratories Inc.: Revenue Share, by Business Unit, 2022
- Figure 49: Bio-Rad Laboratories Inc.: Revenue Share, by Region, 2022
- Figure 50: Exact Sciences Corp.: Annual Revenue, 2020 and 2021
- Figure 51: Exact Sciences Corp.: Revenue Share, by Business Unit, 2022
- Figure 52: Guardant Health Inc.: Annual Revenue, 2021 and 2022
- Figure 53: Guardant Health Inc.: Revenue Share, by Business Unit, 2022
- Figure 54: Guardant Health Inc.: Revenue Share, by Region, 2022
- Figure 55: Illumina Inc.: Annual Revenue, 2021 and 2022
- Figure 56: Illumina Inc.: Revenue Share, by Business Unit, 2022
- Figure 57: Illumina Inc.: Revenue Share, by Region, 2022
- Figure 58: Invitae: Annual Revenue, 2021 and 2022
- Figure 59: Invitae: Revenue Share, by Business Unit, 2022
- Figure 60: Invitae: Revenue Share, by Product, 2022
- Figure 61: Natera Inc.: Annual Revenue, 2021 and 2022
- Figure 62: Natera Inc.: Revenue Share, by Business Unit, 2022
- Figure 63: Natera Inc.: Revenue Share, by Region, 2022
- Figure 64: NeoGenomics Inc.: Annual Revenue, 2021 and 2022
- Figure 65: NeoGenomics Inc.: Revenue Share, by Business Unit, 2022
- Figure 66: Qiagen N.V.: Annual Revenue, 2021 and 2022
- Figure 67: Qiagen N.V.: Revenue Share, by Business Unit, 2022
- Figure 68: Qiagen N.V.: Revenue Share, by Region, 2022
- Figure 69: Sysmex Corp.: Annual Revenue, 2022 and 2023
- Figure 70: Sysmex Corp.: Revenue Share, by Region, 2023

## I would like to order

Product name: Minimal Residual Disease Testing: Global Markets and Technologies

Product link: <https://marketpublishers.com/r/M9926F265F52EN.html>

Price: US\$ 5,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M9926F265F52EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970